A REPORT ON Ranbaxy-Daiichi Deal 1/26/2012 Ranbaxy-Daiichi Deal Introduction: Daiichi Sankyo bought Ranbaxy for $4.6 billion in June 2008. This report studies the implications of the merger between Ranbaxy and Daiichi Sankyo‚ from an intellectual property as well as a market point of view. There are many critical events happening in international pharma market including the growing preference for generics‚ increasing dominance of emerging markets such as India‚ fast approaching patent expiry
Premium Generic drug Ranbaxy Laboratories Pharmaceutical industry
History of Verizon Verizon Communications‚ Inc. was formed on June 30‚ 2000 with the merger of Bell Atlantic Corporation and GTE Corporation‚ in New York City and incorporated in Delaware. On July 3‚ 2000 Verizon began trading on the New York Stock Exchange (NYSE) under the VZ symbol. On March 10‚ 2010 they began trading on the National Association of Securities Dealers Automated Quotations (NASDAQ). The mergers that formed Verizon had roots going back to the beginning of the telephone business in
Premium Verizon Wireless Verizon Communications
MONTHLY M&A INSIDER OCTOBER 2012 A MERGERMARKET REPORT ON GLOBAL M&A ACTIVITY EDITION CONTENTS GLOBAL OVERVIEW AMERICAS: LATIN AMERICA NORTH AMERICA ASIA-PACIFIC EUROPE MIDDLE EAST & AFRICA ABOUT MERRILL CORPORATION 01 09 18 29 41 52 62 MONTHLY M&A INSIDER Part of The Mergermarket Group MERGERMARKET www.mergermarket.com 80 Strand London‚ WC2R 0RL United Kingdom t: +44 (0)20 7059 6100 f: +44 (0)20 7059 6101 sales@mergermarket.com 11 West 19th Street 2nd fl. New York‚ NY
Premium Private equity
Darren Snellgrove Pharmaceutical Mergers: What’s the Rush? Drivers of Recent and Future M&A Activity TABLE OF CONTENTS i) Executive Summary ii) Introduction iii) Industry Structure iv) Reasons for Recent M&A Activity v) Analysis of Two Recent Mega-Mergers – Glaxo Wellcome / SmithKline Beecham
Premium Pharmaceutical industry Pharmacology Drug discovery
REVIEW-------------------------------------------------------------- 5 3. ABOUT M&A--------------------------------------------------------------------------- 6 3.1 TYPES OF MERGER---------------------------------------------------------- 6 3.2 IMPORTANCE OF MERGER----------------------------------------------- 7 3.3 COST AND BENEFIT OF MERGER--------------------------------------- 8 3.4 DOING/CLOSING THE DEAL----------------------------------------------10 4. ANALYSIS--------------------------------------------------------------------------------13
Premium Daimler AG Chrysler Mercedes-Benz
COMPAQ MERGER LIST OF TOPICS S. No. | TOPIC | 1 | Executive Summary | 2 | The IT Industry Profile | 3 | Introduction to the Company Profile – HP and Compaq | 4 | Pre-Merger stats for HP and Compaq | 5 | Relative Performance of HP and Compaq | 6 | HP-Compaq Merger | 7 | Objectives of the Merger | 8 | Expectations from the Merger of HP and Compaq | 9 | Key Points that encouraged the Merger Decision | 10 | Advantages of Merger and Opposition to the Merger |
Premium Hewlett-Packard Mergers and acquisitions
10/6/2014 Case 3: Merck and River Blindness 1. Why was Merck hesitant about developing a human version of Ivermectin? Merck considered this opportunity as a high risk investment. The cost of developing the drug was estimated at $100 million. Even if it was successful to cure river blindness the victims were too poor to afford the drug. There was no way to distribute it in these rural areas were the victims were located. In addition‚ there was a possibility that people would misuse the drugs‚ which
Premium Onchocerciasis Human
bstract: Issues: » Study the synergies of the merger between Hindalco and Novelis » Study the rationale behind Hindalco acquiring a loss making aluminum company » Examine the way the acquisition deal was financed » Analyze whether the deal was overvalued or not » Analyze the trends in the global aluminum industry Keywords: Hindalco Industries Limited‚ Novelis Inc.‚ Merger and Acquisition‚ Deal Valuation‚ Debt-equity Ratio‚ EV/EBITDA Ratio‚ Indian Aluminum Industry‚ Merger Integration‚ Consolidation
Premium Aditya Birla Group Birla family Kumar Mangalam Birla
Mergers and acquisitions (abbreviated M&A) is an aspect of corporate strategy‚ corporate finance and management dealing with the buying‚ selling‚ dividing and combining of different companies and similar entities that can help an enterprise grow rapidly in its sector or location of origin‚ or a new field or new location‚ without creating a subsidiary‚ other child entity or using a joint venture. The distinction between a "merger" and an "acquisition" has become increasingly blurred in various
Premium Mergers and acquisitions
Research proposal Fedorenko Danil Merger. Case of "ExxonMobil". Outcomes Table of content: Literature review Mergers and acquisitions represent the ultimate in change for a business. No other event is more difficult‚ challenging‚ or chaotic as a merger. It is imperative that everyone involved in the process has a clear understanding of how the process works. In the contemporary world mergers and acquisitions are a normal way of life within
Premium Mergers and acquisitions